The role of tanakan in the improvement of the effectiveness of vestibular rehabilitation

Close metadata

Recommended articles:

Vestibular rehabilitation for peripheral vestibular hypofunction: an interdisciplinary consensus. Russian Bulletin of Otorhinolaryngology. 2024;(1):52-63

Rehabilitation in bilateral vestibulopathy: trends and perspectives. Russian Bulletin of Otorhinolaryngology. 2024;(2):59-65

Cochleovestibular manifestations in coronavirus infection. Russian Bulletin of Otorhinolaryngology. 2024;(3):18-23

Electrical vestibular stimulation as a tool for treatment of bilateral vestibular loss. Literature review. Russian Bulletin of Otorhinolaryngology. 2024;(5):51-57

The objective of the present study was to estimate the influence of tanakan on the duration of the period needed to achieve vestibular compensation in the patients presenting with peripheral vestibular dizziness in the course of vestibular rehabilitation with the use of the post-urographic system. 72 patients at the age varying from 18 to 42 years (46 women and 26 men) suffering from peripheral vestibular dizziness were treated on an individual basis for the purpose of vestibular rehabilitation 3-5 times per week for a total period of 3-6 weeks. 42 of the 72 patients comprising group 1 were given Tanakan for 3 months at a dose of 40 mg thrice daily, the remaining 30 patients (group 2) continued to receive the vasoactive treatment as prescribed by attending physicians of other medical and diagnostic centres (protocols of their treatment recommended at local medical facilities did not include tanakan therapy). It is concluded that the use of tanakan for the treatment of the patients presenting with peripheral vestibular dizziness accelerates vestibular compensation and reduces the time necessary to achieve vestibular rehabilitation. Moreover, the combined treatment with the application of tanakan makes it possible to decrease the medicamental loading.

Keywords:

dizziness

balance disorders

post-urography

vestibular rehabilitation

tanakan

EGb 761

Authors:

Zaytseva O.V.

Otdel patologii setchatki i zritel'nogo nerva FGBU "Moskovskiĭ NII glaznykh bolezneĭ im. Gel'mgol'tsa" Minzdravsotsrazvitiia Ross

SPIN RSCI: 4962-5446
ORCID: 0000-0002-4975-1310

List of references:

DeFeudis F.V. A brief history of EGb761 and its therapeutic uses. Pharmacopsych 2003; 36: Suppl 1: 2-7.
Le Bars P.L. Magnitude of effect and special approach to Ginkgo biloba extract EGb761 in cognitive disorders. Pharmacopsych 2003; 36: Suppl 1: 44-49.
Ponto L.L.B., Schultz S.K. Ginkgo biloba extract: Review of CNS effects. Ann Clin Psych 2003; 15: 109-119.
Eckert A., Keil U., Kressmann S., Schindowski K., Leutner S., Leutz S., Müller W.E. Effects of EGb761 Ginkgo biloba extract on mitochondrial function and oxidative stress. Pharmacopsych 2003; 36: Suppl 1: 15-23.
Paniker N.V., Srivastala S.K., Beutler E. Effect of glutathione reductase deficiency on the stimulation of hexose monophosphate shunt under oxidative stress. Biochim Biophys Acta 1970; 215: 456-460.
Luo Y., Packer L. Oxidative Stress and Age-Related Neurodegeneration, Taylor & Francis CRC Press, Florida 2005; 528.
Bourdel-Marchasson I., Delmas-Beauvieux M.C., Peuchant E., Richard-Harston S., Decamps A., Reignier B., Emeriau J.P., Rainfray M. Antioxidant defenses and oxidative stress markers in erythrocytes and plasma from normally nourished elderly Alzheimer patients. Age Ageing 2001; 30: 235-241.
Moreira P.I., Siedlak S.L., Aliev G., Zhu X., Cash A.D., Smith M.A., Perry G. Oxidative stress mechanisms and potential therapeutics in Alzheimer disease. J Neural Transm 2005; 112: 921-932.
Brandt T., Schautzer F, Hamilton D.A., Bruning R., Markowitsch H.J., Kalla R., Darlington C., Smith P., Strupp M. Vestibular loss causes hippocampal atrophy and impaired spatial memory in humans. Brain 2005; 128: 11: 2732-2741.
Hanes D.A., McCollum G. Cognitive-vestibular interactions: A review of patient difficulties and possible mechanisms. Journal of Vestibular Research 2006; 16: 75-91.
Smith P.F., Zheng Y., Horii A. Does vestibular damage cause cognitive dysfunction in humans? J Vestibul Res 2005; 15: 1-9.
Redfern M.S., Talkowski M.E., Jennings J.R., Furman J.M. Cognitive influences in postural control of patients with unilateral vestibular loss. Gait Posture 2004; 19: 2: 105-114.
Oken B.S. Ginko biloba. In: Evidence-based Dementia Practice. Ed. by N. Qizilbash, L.S. Schneider, H. Chui, P. Tariot, H. Brodaty, J. Kaye, T. Erkinjuntti. Oxford: Blackwell Sciences 2002; 518-523.
Zimmermann M., Colciaghi F., Cattabeni F., Di Luca M. Ginkgo biloba extract: from molecular mechanisms to the treatment of Alzheimer's disease. Cell Molec Biol 2002; 48: 613-623.
Stackman R.W., Eckenstein F., Frei B., Kulhanek D., Nowlin J., Quinn J.F. Prevention of age-related spatial memory deficits in a transgenic mouse model of Alzheimer's disease by chronic Ginkgo biloba treatment. Exp Neurol 2003; 184: 510-520.
Orendors-Fraczkowska K., Pospiech L., Gawron W. Results of combined treatment for vestibular receptor impairment with physical therapy and Ginkgo biloba extract (Egb 761). Otolaryngol Pol 2002; 56: 1: 83-88.
Heide W., Adlung BB. , Hörr R., Kömpf D. Schwindel und Nystagmus bei zentral-vestibularen Ischamien: eine Placebo-kontrollierte Therapiestudie mit Ginkgo-biloba-Extrakt EGb 761. Aktuelle Neurologie 1998; 25: 94.
Clissold S. From Subjective Memory Impairment to Alzheimer's Disease: Tanakan (EGb761) in Perspective. Exp Rev o Neurotherар 2010; 11: 5: 627-637.

Close metadata